The Quigley Corporation Introduces COLD-EEZE® Nasal Spray; Contains Zinc Gluconate To Treat Common Cold and Aloe Vera to Soothe Nasal Passages

DOYLESTOWN, PA, February 25, 2003 (BUSINESS WIRE) -- The Quigley Corporation (Nasdaq:QGLY) originator of the zinc cold product category, announced today the launch of a new offering in its COLD-EEZE® line of remedies.

The product, a moisturizing nasal spray containing the active ingredient Zinc Gluconate and also containing Aloe Vera gel, will begin shipping to retail in July.

The new COLD-EEZE® Nasal Spray is designed to effectively reduce the duration of symptoms of the common cold. Its 0.68 mg of Zinc Gluconate per dose penetrates nasal, sinus and throat cavities to deliver the zinc ions where they are needed most. Additionally, the spray contains Aloe Vera gel to help soothe nasal passages that are dry and inflamed. The formula is non-habit forming and will not interact with other medicines.

"The COLD-EEZE® Nasal Spray, manufactured under U.S. patent #5,622,724, leverages our strong equity in cold care and broadens our portfolio of zinc cold remedies," said Guy Quigley, president and CEO of the Quigley Corporation. "Along with the proven efficacy of our lozenges and gum, the new Nasal Spray complements our existing COLD-EEZE® line while offering consumers a new alternative in their fight to get better faster."

The COLD-EEZE® Nasal Spray will be sold in a dynamic package that allows consumers to recognize the product as part of the COLD-EEZE® line. The launch of the Nasal Spray will be supported with an integrated marketing campaign, including advertising, public relations and in-store support.

Study Shows: Treat it with the COLD-EEZE® Lozenges
In a retrospective study conducted over three years at the Heritage School facility in Provo, Utah, 378 adolescents ranging in age from 12 to 18 were given COLD-EEZE® both prophylactically and symptomatically for more than 170,000 patient days. The study found that COLD-EEZE®, when taken daily, statistically lessened the number of colds study participants suffered per year by over 50%. The colds that did develop lasted for an average period of 6 days when treated with COLD-EEZE® and 10 days when not. The study also found that the use of COLD-EEZE® to treat a cold statistically reduced antibiotic use for respiratory illnesses by 92%.

In a double-blind, placebo-controlled study conducted at the Cleveland Clinic and published in the Annals of Internal Medicine, those patients taking COLD-EEZE® recovered completely from their colds more than three days faster (on average) than the patients who received a placebo. In addition, individual symptoms went away faster. On average, the COLD-EEZE® group had 2.5 fewer days of coughing, 1 less day of headache, 1 less day of hoarseness, 2 fewer days of nasal congestion, 3 fewer days of nasal drainage and 2 fewer days of sore throat.

About The Quigley Corporation
The Quigley Corporation (NASDAQ: QGLY) is a leading developer and marketer of diversified health products including the Cold-Eeze® family of patented zinc gluconate glycine (ZIGG(tm)) lozenges, gums and sugar free tablets. Cold-Eeze is the only (ZIGG(tm)) lozenge proven in two double-blind studies to reduce the duration of the common cold from 7.6 to 4.4 days or by 42%. In addition to Over-The-Counter (OTC) products, the Company has formed Quigley Pharma Inc. (www.QuigleyPharma.com), a wholly owned ethical pharmaceutical subsidiary, to introduce a line of patented prescription drugs. The Quigley Corporation's customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies.